Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2026-05-13 Share Issue/Capital Cha…
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - OCC 8 pages 20.7KB
Share Issue/Capital Change Classification · 92% confidence The document is the ASX Listing Rule Appendix 2A “Application for quotation of securities,” detailing the issue and quotation of 500,000 new shares following option conversions. This is a regulatory announcement of a new share issue/capital change rather than a financial report or mere publication notice. It fits the “Share Issue/Capital Change” category.
2026-05-13 English
Cleansing Notice 2 pages 597.8KB
Share Issue/Capital Change Classification · 92% confidence The document is an ASX announcement notifying the market under section 708A of the Corporations Act that the Company has issued 500,000 new fully paid ordinary shares following option exercise. This is a routine announcement of a new share issue (capital change), matching the definition of Share Issue/Capital Change (SHA).
2026-05-13 English
Application for quotation of securities - OCC 8 pages 21.5KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement used for the application for quotation of securities. It details the issuance and quotation of securities resulting from options being exercised or convertible securities being converted. The document includes specifics such as the number of securities, issue dates, and whether the securities are to be quoted on the ASX. This type of document is not a financial report, earnings release, or management discussion, but rather a formal announcement related to capital changes and securities quotation. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not merely an announcement of a report but a substantive filing about securities issuance and quotation.
2026-05-04 English
Cleansing Notice 2 pages 597.7KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement from Orthocell Limited dated 5 May 2026. It provides a notice under Section 708A(5)(e) of the Corporations Act regarding the issuance of fully paid ordinary shares following the cashless exercise of employee options. The content focuses on compliance with disclosure exemptions under the Corporations Act and the immediate tradability of the new shares. There is no financial data, earnings information, or detailed report content. The document is a regulatory announcement about a share issue event, specifically a notice under the Corporations Act, which fits the category of Share Issue/Capital Change announcements. The document length is 4143 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2026-05-04 English
Appendix 3Y - John Van Der Wielen 2 pages 220.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director's Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares/options held before and after the change, nature of the transaction (on-market purchase), and dates. This matches the definition of a Director's Dealing report, which involves personal share transactions by company directors and executives. The document is not a full financial report, nor an announcement of a report, but a specific insider transaction notice.
2026-05-03 English
Appendix 3Y - Michael McNulty 2 pages 219.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director's Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares before and after the change, nature of the interest, and transaction details. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document length is 3502 characters, which is consistent with a detailed notice rather than a brief announcement. There is no indication that this is an annual report, audit report, or any other type of filing. Therefore, the correct classification is Director's Dealing (DIRS).
2026-05-03 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.